# Enumeral Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enumeral-biomedical

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.enumeral.com
- Total disclosed funding: $2M
- Latest round: Series B (May 7, 2014)
- Investors on record: 2

## About

Enumeral Biomedical is a biotechnology company focused on leveraging advanced technologies to uncover critical insights in immunotherapy and cancer treatment.Founded in 2009 and headquartered in New York, US, Enumeral Biomedical specializes in innovative biotechnological solutions. The company has undergone significant strategic pivots to enhance its research capabilities. In August 2014, it raised USD 21.5 mn in PIPE funding, led by Montrose Capital Partners with participation from 180 Degree Capital. The total amount raised to date is USD 21.5 mn, encompassing six deals since its inception.Enumeral Biomedical employs a unique platform to facilitate the discovery of immune system interactions and their implications in cancer therapy. It serves a broad clientele, including pharmaceutical companies and research institutions, aiming to improve therapeutic outcomes through enhanced understanding of immune responses. The company's offerings are particularly focused on the North American and European markets, where there is a growing demand for innovative cancer treatment solutions.In the most recent year, 2016, Enumeral Biomedical reported a revenue of USD 2,452,868. The company's financial performance indicated an EBITDA of USD -6,363,868 for the same year, reflecting the ongoing investments in R&D and operational capabilities.Enumeral Biomedical’s recent PIPE funding of USD 21.5 mn is earmarked for advancing its research and development initiatives, with plans to launch new products aimed at enhancing cancer therapies by 2025. The company is also strategizing to expand its presence in European markets, specifically targeting collaborations with leading pharmaceutical firms, which is anticipated to further establish its footprint in the biotechnology landscape.

## Funding rounds

- Series B, May 7, 2014, $2M — 180 Degree Capital, Harris & Harris, Ltd.

## Investors

- 180 Degree Capital (https://capitalatlas.ai/funds/180-degree-capital) — Series B
- Harris & Harris, Ltd. — Series B